4-styryl-phenylboronic acid | 231606-49-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-styryl-phenylboronic acid
• 英文别名: [4-(2-Phenylethenyl)phenyl]boronic acid
• CAS: 231606-49-8
• 化学式: C₁₄H₁₃BO₂
• 分子量: 224.067
• InChiKey: RAHFHNVYCKLZGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-styryl-phenylboronic acid 生成 (2R, 4S)-5-oxo-4-(4-phenethylphenyl)-pyrrolidine-2-carboxylic acid hydroxyamide
  参考文献：
  名称：

  5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives

  摘要：

  本发明涉及一种化合物，其化学式为##STR1##其中R.sup.1，R.sup.2，R.sup.3如上所定义，以及制药组合物和治疗方法。

  公开号：

  US06114361A1

文献信息

• Stereoselective Rh^I-Catalyzed Tandem Conjugate Addition of Boronic Acids−Michael Cyclization
  作者：Cristina Navarro、Aurelio G. Csákÿ

  DOI：10.1021/ol702571c

  日期：2008.1.1

  The first examples of the stereoselective sequence RhI-catalyzed tandem conjugate addition of boronic acids to enones-Michael cyclization, is reported. The reaction is carried out in dioxane-H2O at rt, and 1,2,3-trisubstituted indans are obtained in a highly regio- and stereoselective fashion.

  报道了硼酸向烯酮-迈克尔环化的立体选择性序列RhI催化的串联共轭加成的第一个实例。该反应在室温下于二恶烷-H 2 O中进行，并且以高度区域选择性和立体选择性的方式获得1,2,3-三取代的茚满。
• Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the β-exosite
  作者：Garry R. Smith、Dejan Caglič、Petr Čapek、Yan Zhang、Sujata Godbole、Allen B. Reitz、Tobin J. Dickerson

  DOI：10.1016/j.bmcl.2012.04.019

  日期：2012.6

  Botulinum neurotoxins (BoNTs) are the most toxic proteins known to man, exposure to which results in flaccid paralysis. Given their extreme potency, these proteins have become studied as possible weapons of bioterrorism; however, effective treatments that function after intoxication have not progressed to the clinic. Here, we have reexamined one of the most effective inhibitors, 2,4-dichlorocinnamyl hydroxamate, in the context of the known plasticity of the BoNT/A light chain metalloprotease. Our studies have shown that modifications of this compound are tolerated and result in improved inhibitors, with the best compound having an IC50 of 0.23 mu M. Given the inconsistency of structure-activity relationship trends observed across similar compounds, this data argues for caution in extrapolating across structural series (C) 2012 Elsevier Ltd. All rights reserved.